- Home
- IMMX vs JMM Comparison
IMMX vs JMM Comparison
Compare IMMX & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- JMM
- Stock Information
- Founded
- IMMX 2014
- JMM 1988
- Country
- IMMX United States
- JMM United States
- Employees
- IMMX N/A
- JMM N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- JMM Trusts Except Educational Religious and Charitable
- Sector
- IMMX Health Care
- JMM Finance
- Exchange
- IMMX Nasdaq
- JMM Nasdaq
- Market Cap
- IMMX 50.1M
- JMM 57.2M
- IPO Year
- IMMX 2021
- JMM N/A
- Fundamental
- Price
- IMMX $2.09
- JMM $6.12
- Analyst Decision
- IMMX Strong Buy
- JMM
- Analyst Count
- IMMX 1
- JMM 0
- Target Price
- IMMX $7.00
- JMM N/A
- AVG Volume (30 Days)
- IMMX 59.6K
- JMM 16.1K
- Earning Date
- IMMX 05-20-2025
- JMM 01-01-0001
- Dividend Yield
- IMMX N/A
- JMM 5.44%
- EPS Growth
- IMMX N/A
- JMM N/A
- EPS
- IMMX N/A
- JMM N/A
- Revenue
- IMMX N/A
- JMM N/A
- Revenue This Year
- IMMX N/A
- JMM N/A
- Revenue Next Year
- IMMX N/A
- JMM N/A
- P/E Ratio
- IMMX N/A
- JMM N/A
- Revenue Growth
- IMMX N/A
- JMM N/A
- 52 Week Low
- IMMX $1.26
- JMM $5.29
- 52 Week High
- IMMX $2.71
- JMM $6.10
- Technical
- Relative Strength Index (RSI)
- IMMX 61.41
- JMM 54.56
- Support Level
- IMMX $1.92
- JMM $5.97
- Resistance Level
- IMMX $2.25
- JMM $6.16
- Average True Range (ATR)
- IMMX 0.17
- JMM 0.09
- MACD
- IMMX 0.03
- JMM 0.02
- Stochastic Oscillator
- IMMX 67.61
- JMM 85.19
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.